Institutional investors purchased a net $1.2 million shares of RGEN during the quarter ended June 2016 and now own 92.11% of the total shares outstanding. This majority interest is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
WILLIAM BLAIR INVESTMENT MANAGEM... Bought 511.3 Thousand shares of Repligen Corp
THEAM SAS Bought 246.5 Thousand shares of Repligen Corp
RUSSELL INVESTMENT MANAGEMENT LL... Bought 209.8 Thousand shares of Repligen Corp